Tambi Brian 4

4 · Insys Therapeutics, Inc. · Filed May 14, 2018

Form 4

Period: 2018-02-21

Director

Transactions

Award
Common Stock
2018-02-21+4,000→ 4,000 total
Exercise/Conversion
Common Stock
2018-05-10$0.61/sh+33,654$20,529→ 37,654 total
Exercise/Conversion
Common Stock
2018-05-10$1.62/sh+68,850$111,537→ 106,504 total
Exercise/Conversion
Common Stock
2018-05-10$3.63/sh+60,000$217,800→ 166,504 total
Sale
Common Stock
2018-05-10$6.41/sh−166,504$1,067,291→ 0 total
Disposition to Issuer
Restricted Stock Units
2018-02-21−4,000→ 0 total
→ Common Stock (4,000 underlying)
Exercise/Conversion
Stock Option (right to buy)
2018-05-10−33,654→ 0 total
Exercise: $0.61Exp: 2020-02-21→ Common Stock (33,654 underlying)
Exercise/Conversion
Stock Option (right to buy)
2018-05-10−68,850→ 0 total
Exercise: $1.62Exp: 2021-03-28→ Common Stock (68,850 underlying)
Exercise/Conversion
Stock Option (right to buy)
2018-05-10−60,000→ 0 total
Exercise: $3.63Exp: 2023-05-13→ Common Stock (60,000 underlying)

Footnotes (5)

[F1]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.28 to $6.61 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F2]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
[F3]The restricted stock units ("RSUs") vested on the one year anniversary of the date of grant.
[F4]The exercise price reflects a 3-for-2 forward stock split effected by the Issuer on March 28, 2014 and a 2-for-1 forward stock split effected by the Issuer on June 5, 2015.
[F5]The option is fully vested and exercisable.

Documents

1 file